Head & Neck/Thyroid Cancers
From the Editor
Balancing clinical and supportive care at every step of the disease continuum
News
Suicide rate high in patients with head and neck cancer
Key clinical point: Patients with head and neck cancer have a significantly higher suicide rate than the general population. Major finding: The...
Conference Coverage
Experimental LOXO-101 induces regression in several hard-to-treat cancers
Key clinical point:Inhibition of TRK gene fusion products is a novel strategy for treating cancer. Major finding: Three of three patients...
News
Adjuvant lapatinib added no benefit against head and neck squamous cell carcinoma
Key clinical point: After surgery for high-risk squamous cell carcinoma of the head and neck, the addition of lapatinib to chemoradiotherapy and...
Conference Coverage
ITC: Study provides first evidence of paclitaxel benefit for anaplastic thyroid cancer
Weekly infusions of paclitaxel delayed progression in some patients with the very aggressive anaplastic thyroid cancer, a small prospective study...
News
ASTRO: Less intense chemoradiation may be possible for HPV-related oropharyngeal cancers
Patients who have low-risk human papillomavirus (HPV)–associated oropharyngeal cancers may be effectively and safely treated with a reduced...
Conference Coverage
Increased surveillance may explain post-Fukushima pediatric thyroid cancers
The increased incidence of thyroid cancers in Japanese youth after the Fukushima nuclear accident may be an artifact of increased surveillance.
Conference Coverage
Percutaneous ethanol effective for small papillary thyroid cancers
Key clinical point: Ultrasound-guided percutaneous ethanol ablation (UPEA) is an efficacious, cost-effective, and noninvasive definitive treatment...
News
RFA, ethanol ablation equally effective for thyroid nodules
Key clinical point: Radiofrequency ablation and ethanol ablation were similarly effective in treating cystic thyroid nodules. Major finding: At 6...
Conference Coverage
ITC: SELECT trial: Lenvatinib effects similar regardless of site, number of metastases
Outcomes in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib did not differ based on metastatic site,...
Conference Coverage
Thyroglobulin can’t predict pazopanib response in differentiated thyroid cancer
Key clinical point: Falling thyroglobulin levels cannot predict early response to pazopanib in differentiated thyroid cancers. Major finding:...